Turn Therapeutics® announces completion of human trial for GX-03 intranasal drug candidate for the treatment of mild/moderate COVID-19

While systemic interventions exist for the treatment of moderate/severe COVID-19, few options exist for early intervention in an effort to prevent disease progression and subsequent hospitalization.

Our intranasal antiviral candidate has shown a dramatic reduction in time to 60% viral load reduction over placebo, thus achieving its primary endpoint and warranting further research as a potential early intervention to reduce disease severity of COVID-19 and other respiratory viruses. GX-03 has a multi-year history of safety and efficacy in advanced wound and dermatologic management.


In laboratory testing, GX-03 showed a dramatic ability to eliminate [over 98% of Human Coronavirus within just 2 hours]. Notably, over 80% of this elimination took place in the first 10 minutes.

Proposed Mechanism of Action

Media Inquiries

If you have media requests, please fill out the quick contact form. You can read more about Hexagen® in the press through these links:

Turn Therapeutics Reaches Licensing and Distribution Agreement with MIMEDX